Grail Shares Plunge Following Clinical Trial Setback

Friday witnessed a dramatic sell-off in Grail’s stock, triggered by disappointing news from a major clinical study. While the core objective of the large-scale NHS Galleri trial was not met, a deeper look at the details and the latest financial results reveals a more nuanced picture. The key question for investors is whether the company’s substantial cash reserves can offset the severe loss of market confidence.

Amid the clinical news, Grail released its fiscal year 2025 results, which provided some counterbalance to the negative sentiment. The company reported fourth-quarter revenue of $43.6 million, a 14% increase year-over-year. This growth was driven significantly by its U.S. operations, where sales of the Galleri Read more...